Tech secretary to slash red tape in bid to boost tech growth
Technology secretary Peter Kyle has pledged to strip away outdated regulations that delay cutting-edge technology like medical delivery drones and AI powered healthcare solutions.
Speaking at the TechUK conference on Monday, Kyle said that 'there is no route to long term growth without innovation'.
He also announced plans for the first ever dedicated strategy for the digital and technology sector, which is centred on pro-innovation regulation.
Kyle highlighted the urgent need to remove unnecessary barriers that slow down new technology.
He cited an ongoing trial in London where medical drones are speeding up blood sample deliveries, a project that could be derailed by a single nose complaint.
Under the government's new approach, such regulatory obstacles will be removed to ensure tech reaches the market quickly and safely.
To lead this transformation, former science minister Lord David Willetts has been appointed as the first chair of the Regulatory Innovation Office (RIO), tasked with modernising rules to accelerate game-changing technology.
The government is also investing in cutting edge technology, with Kyle announcing £12m for ten winners of Innovate UK's quantum missions pilot, to advance quantum computing and networking.
Kyle also outlined how the government's Invest 2035 strategy will harness engineering biology, AI, semiconductors, cyber, quantum, and telecoms to build a stronger economy and improve lives across the UK.
He emphasised that the nation must be a stable partner for researchers and businesses, working alongside them to tackle the biggest challenges of the decade ahead.
Lord Willetts, now leading the RIO, said he was 'honoured to shape regulatory approaches that empower new technologies'.
This comes as the government announces its plans to hit regulators with performance targets to drive innovation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Reefs made from human ashes could revive British seabeds, says startup
Death is killing our planet. That is the stark assessment of a new business offering an innovative alternative: to have your loved one's ashes made into a reef and anchored to the British seabed. There are increasing concerns about the environmental cost of traditional funerals: a single burial generates 833kg of CO2, while a typical cremation has a footprint of about 400kg CO2. In addition, 1.6m tonnes of concrete and 14,000 tonnes of steel is used every year for building graves in the US. Chemicals from embalming processes seep into the soil. But now a British startup, Resting Reef, is redefining what a cemetery can be by turning the ashes of humans into memorial reef structures. 'Cemeteries should be places that reconnect us with nature and remind us that we're part of a larger ecosystem,' said Aura Pérez, the company's co-founder who met her business partner, Louise Skajem, when they were doing their masters at the Royal College of Art and Imperial College London. Resting Reef uses aquamation, an alkaline process for cremation, to combine pet or human ashes with crushed oyster shells and concrete into a material proven to enhance marine growth. 'Artificial oyster reefs can help regenerate marine growth but 85% have been lost due to human activities, so we are using animal and human ashes to replace them,' said Perez. The formula is then 3D printed into reef structures designed to create diverse habitats for a variety of fish species through differing heights, textures and tunnel systems. When the reef is ready, it is anchored to the seabed at a depth of about 10 metres where it will regenerate marine biodiversity, filter water and prevent coastal erosion. The reefs can capture as much as 2.2m kg of CO2 in three years. Resting Reef began incorporating the ashes of pets into artificial reefs in Bali, Indonesia, last year. But demand has been so great that the company is opening up the offer to humans. The company is working to secure licences to replace degraded seabeds with artificial reefs at the Plymouth Breakwater on the south coast of England, a 1,560m stone breakwater protecting the Plymouth Sound. 'It's time for the death industry to change: we want to shift the industry from focusing on death, to life and regenerate growth,' said Pérez. The business has won the Terra Carta Design Lab, a global competition established by King Charles and the British designer Sir Jony Ive, and an Innovate UK grant. The co-founders were named in the Forbes 30 Under 30 list for Social Impact in Europe. 'We conducted a pilot reef in Bali in 2024, collaborating with the local Balinese community,' said Pérez. 'We have placed 24 memorial reefs for beloved cats, dogs, lizards, fish and exotic birds for owners in the US, UK and other countries. 'The pilot project attracted 59 fish species and achieved fish diversity 12 times greater than nearby degraded areas,' she added. 'This is very exciting.' 'We do not see ourselves working with death but rather providing better lives for coming generations by changing a very polluting industry and practice,' said Skajem, whose masters was on the decline of oyster reefs and coral reefs due to the climate crisis and human activities. Resting Reefs hopes to have the UK licences in 2026 and establish the first reef six to 12 months later. Human memorials have an initial cost of £3,900 although families can pay more for a range of curated activities at the site. Prof Rick Stafford, who specialises in artificial reefs and marine biodiversity at Bournemouth University, praised the company for increasing local biodiversity. 'Resting Reefs is different from other companies because it focuses on enhancing biodiversity close to the shore,' he said. 'It's entirely in line with environmental policies like protecting 30% of the world's land and sea by 2030, and the Marine Net Gain policy to ensure developments in the marine environment leave the ecosystem in a better state than before, with a focus on improving biodiversity.' Peter Holt, director and co-founder of the Plymouth-based Ships project, a marine consultancy service, also praised the business. 'I'm very excited by the project and its potential to improve marine habitats and support a range of maritime industries,' he said. 'The project has received support from the whole community here, including the King's Harbour Master, because it will potentially boost diving tourism and fishing, while aligning with the Plymouth Sound national marine park's goals to re-engage the public with marine life.'
Yahoo
a day ago
- Yahoo
Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
Grant forms part of £1.2M project to customise Tagomics' multiomic profiling platform for early detection of colorectal cancer Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's InterlaceTM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: "We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes." Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: "The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes." For more information about Tagomics, please visit: View source version on Contacts Media: Francesca Sign in to access your portfolio
